Efficacy of 6-mercaptopurine treatment after azathioprine hypersensitivity in inflammatory bowel disease

Table 2 Changes of CDAI/CAI, CRP, ESR, WBC, PLT variables in the third group (mean ± SD)

Disease	Months	CDAI	CAI	CRP	ESR	WBC	PLT
UC	0	-	7.8 ± 6.3	16 ± 10	30.4 ± 16.2	9.3 ± 3.3	384 ± 175
UC	3	-	6.9 ± 6	8.3 ± 3.5	28.3 ± 16.5	10.3 ± 4.5	336 ± 119
UC	6	-	6.1 ± 6.7	11 ± 19	31.9 ± 32.7	6.8 ± 2	348 ± 197
UC	12	-	1.1 ± 1	4.6 ± 3.5	27 ± 17.2	6.1 ± 2.6	283 ± 87
CD	0	146 ± 128	-	39.8 ± 26.7	41.3 ± 11.6	9.9 ± 2.7	431 ± 136
CD	3	145 ± 124	-	23.3 ± 10.7	29.2 ± 14.1	7 ± 3	332 ± 66
CD	6	167 ± 68	-	21 ± 15	17.6 ± 28.6	9.9 ± 4.2	317 ± 89
CD	12	46 ± 56	-	6 ± 4	18 ± 14.7	6.2 ± 1.3	247 ± 80